This “Charcot Marie Tooth disease - Pipeline Insight, 2026” report provides comprehensive insights about 13+ companies and 15+ pipeline drugs in Charcot Marie Tooth disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The disease is characterized by progressive weakness and sensory loss that typically begins in the feet and legs before extending to the hands and arms. Common manifestations include muscle wasting, foot abnormalities such as high arches and hammertoes, and challenges with balance, coordination, and fine motor skills. Patients may also report numbness, pain, fatigue, and occasional tremors in affected regions. The age of onset and rate of progression can vary significantly among individuals, reflecting the genetic diversity of the disorder.
Diagnosis of Charcot-Marie-Tooth disease is based on a combination of clinical assessment, electrophysiological testing, and genetic analysis. Physicians evaluate presenting symptoms, muscle strength, reflexes, and characteristic foot deformities during physical examination. Nerve conduction studies and electromyography are used to differentiate between demyelinating and axonal forms of the disease. Confirmation is achieved through genetic testing to identify specific mutations, while imaging techniques and, in rare cases, nerve biopsy may be utilized in complex presentations.
Treatment of Charcot-Marie-Tooth disease is primarily supportive, as no definitive cure currently exists, with the goal of alleviating symptoms and preserving mobility and quality of life. Management strategies include physical and occupational therapy, the use of orthotic supports, and, in some cases, surgical interventions to correct deformities and improve function. Pain control is individualized, often involving medications to address neuropathic pain and muscle cramps. Emerging approaches such as gene therapy and HDAC6 inhibition are being explored to address the underlying disease mechanisms in specific subtypes.
"Charcot Marie Tooth disease- Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Charcot Marie Tooth disease pipeline landscape is provided which includes the disease overview and Charcot Marie Tooth disease treatment guidelines. The assessment part of the report embraces, in depth Charcot Marie Tooth disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Charcot Marie Tooth disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This product will be delivered within 2 business days.
Charcot Marie Tooth disease: Understanding
Charcot Marie Tooth disease: Overview
Charcot-Marie-Tooth disease is a group of hereditary neurological disorders caused by genetic mutations that disrupt the structure and function of peripheral nerves. It involves both motor and sensory nerve impairment, resulting in progressive muscle weakness, sensory deficits, and limb deformities. Symptoms often emerge during adolescence or early adulthood and gradually worsen over time, affecting mobility and coordination. The condition is highly heterogeneous, with more than 100 implicated genes, including PMP22, MPZ, and GJB1, and is classified into subtypes such as CMT1, CMT2, and CMTX.The disease is characterized by progressive weakness and sensory loss that typically begins in the feet and legs before extending to the hands and arms. Common manifestations include muscle wasting, foot abnormalities such as high arches and hammertoes, and challenges with balance, coordination, and fine motor skills. Patients may also report numbness, pain, fatigue, and occasional tremors in affected regions. The age of onset and rate of progression can vary significantly among individuals, reflecting the genetic diversity of the disorder.
Diagnosis of Charcot-Marie-Tooth disease is based on a combination of clinical assessment, electrophysiological testing, and genetic analysis. Physicians evaluate presenting symptoms, muscle strength, reflexes, and characteristic foot deformities during physical examination. Nerve conduction studies and electromyography are used to differentiate between demyelinating and axonal forms of the disease. Confirmation is achieved through genetic testing to identify specific mutations, while imaging techniques and, in rare cases, nerve biopsy may be utilized in complex presentations.
Treatment of Charcot-Marie-Tooth disease is primarily supportive, as no definitive cure currently exists, with the goal of alleviating symptoms and preserving mobility and quality of life. Management strategies include physical and occupational therapy, the use of orthotic supports, and, in some cases, surgical interventions to correct deformities and improve function. Pain control is individualized, often involving medications to address neuropathic pain and muscle cramps. Emerging approaches such as gene therapy and HDAC6 inhibition are being explored to address the underlying disease mechanisms in specific subtypes.
"Charcot Marie Tooth disease- Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Charcot Marie Tooth disease pipeline landscape is provided which includes the disease overview and Charcot Marie Tooth disease treatment guidelines. The assessment part of the report embraces, in depth Charcot Marie Tooth disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Charcot Marie Tooth disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Charcot Marie Tooth disease R&D. The therapies under development are focused on novel approaches to treat/improve Charcot Marie Tooth disease.Charcot Marie Tooth disease Emerging Drugs Chapters
This segment of the Charcot Marie Tooth disease report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.Charcot Marie Tooth disease Emerging Drugs
Ignaseclant: NMD PHARMA
Ignaseclant (NMD670) is an investigational, first-in-class oral small molecule that selectively inhibits the skeletal muscle chloride channel ClC-1 chloride channel. By regulating this channel, it increases muscle excitability and enhances neuromuscular signal transmission. The therapy is being developed to improve muscle function and alleviate fatigue in patients with Charcot-Marie-Tooth disease. It is currently undergoing Phase II clinical evaluation for the treatment of Charcot-Marie-Tooth disease.EN001: ENCell
EN001 is an investigational therapeutic being developed for the treatment of Charcot-Marie-Tooth disease, a genetic disorder characterized by progressive muscle weakness and sensory loss. The drug is designed to enhance neuromuscular function by targeting pathways involved in muscle strength and nerve signaling. By improving muscle performance and reducing fatigue, EN001 aims to address key functional impairments associated with the disease. The drug has recently completed Phase I of clinical trials.Charcot Marie Tooth disease: Therapeutic Assessment
This segment of the report provides insights about the different Charcot Marie Tooth disease drugs segregated based on following parameters that define the scope of the report, such as:Major Players in Charcot Marie Tooth disease
- There are approx. 13+ key companies which are developing the therapies for Charcot Marie Tooth disease. The companies which have their Charcot Marie Tooth disease drug candidates in the most advanced stage, i.e. Phase II include, NMD PHARMA.
Phases
The report covers around 15+ products under different phases of clinical development like:
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Charcot Marie Tooth disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Molecule Type
Products have been categorized under various Molecule types such as:
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.Charcot Marie Tooth disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Charcot Marie Tooth disease therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Charcot Marie Tooth disease drugs.Charcot Marie Tooth disease Report Insights
- Charcot Marie Tooth disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Charcot Marie Tooth disease Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Charcot Marie Tooth disease drugs?
- How many Charcot Marie Tooth disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Charcot Marie Tooth disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Charcot Marie Tooth disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Charcot Marie Tooth disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- NMD PHARMA A/S
- ENCell
- Novartis
- Elpida Therapeutics
- Augustine Therapeutics
- Armatus Bio
Key Products
- Ignaseclant
- EN001
- EDK060
- ELP-0
- AGT-100216
- TVR110
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive SummaryCharcot Marie Tooth disease- Analytical PerspectiveCharcot Marie Tooth disease Key CompaniesCharcot Marie Tooth disease Key ProductsCharcot Marie Tooth disease- Unmet NeedsCharcot Marie Tooth disease- Market Drivers and BarriersCharcot Marie Tooth disease- Future Perspectives and ConclusionCharcot Marie Tooth disease Analyst ViewsCharcot Marie Tooth disease Key CompaniesAppendix
Charcot Marie Tooth disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Ignaseclant: NMD PHARMA A/S
Mid Stage Products (Phase II)
Drug Name: Company Name
Early Stage Products (Phase I)
EN001: ENCell
Preclinical and Discovery Stage Products
Inactive Products
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- NMD PHARMA A/S
- ENCell
- Novartis
- Elpida Therapeutics
- Augustine Therapeutics
- Armatus Bio
